Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells

[1]  Franziska Michor,et al.  Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. , 2011, Blood.

[2]  Jiankai Xu,et al.  Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. , 2011, International journal of oncology.

[3]  P. Lichter,et al.  Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells , 2010, Clinical Cancer Research.

[4]  M. Pirity,et al.  Embryoid body formation from embryonic and induced pluripotent stem cells: Benefits of bioreactors. , 2009, World journal of stem cells.

[5]  A. Hao,et al.  Oct4 is expressed in human gliomas and promotes colony formation in glioma cells , 2009, Glia.

[6]  Baofeng Yang,et al.  Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. , 2009, Basic & clinical pharmacology & toxicology.

[7]  Gideon Rechavi,et al.  MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. , 2008, Biochemical and biophysical research communications.

[8]  P. Kovanen,et al.  KIT overexpression induces proliferation in astrocytes in an imatinib‐responsive manner and associates with proliferation index in gliomas , 2008, International journal of cancer.

[9]  A. Shiau,et al.  Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. , 2008, Cancer research.

[10]  E. Holland,et al.  Glioma Formation, Cancer Stem Cells, and Akt Signaling , 2008, Stem Cell Reviews.

[11]  U. Bogdahn,et al.  CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors , 2008, Brain pathology.

[12]  D. Rowitch,et al.  Glioma Stem Cells: A Midterm Exam , 2008, Neuron.

[13]  L. Ricci-Vitiani,et al.  Mesenchymal differentiation of glioblastoma stem cells , 2008, Cell Death and Differentiation.

[14]  S. Fitter,et al.  Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.

[15]  S. Schiffmann,et al.  Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease , 2008, Molecular and Cellular Neuroscience.

[16]  N. Banik,et al.  Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells , 2008, Journal of Neuro-Oncology.

[17]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[18]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[19]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[20]  S. Gústafsdóttir,et al.  Autocrine/paracrine platelet-derived growth factor regulates proliferation of neural progenitor cells. , 2006, Cancer research.

[21]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[22]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Franssila,et al.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Fuller,et al.  Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. , 2004, Neuron glia biology.

[25]  L. Puricelli,et al.  EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas , 2004, Journal of surgical oncology.

[26]  K. Camphausen,et al.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. , 2003, Cancer research.

[27]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  C. Holding,et al.  Human embryonic genes re-expressed in cancer cells , 2001, Oncogene.

[30]  D. George,et al.  Platelet-derived growth factor receptors: a therapeutic target in solid tumors. , 2001, Seminars in oncology.

[31]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[32]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[33]  F. Gage,et al.  Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[35]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.